Valuation, from the filing
| Public float | $2.50B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $9.60 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 13.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 0.4× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 3.3× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
13.4× earnings today, against a median of 6.1× across 5 years on record. Above its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $2.50B | 13.4× | |
| 2024-06-30 | $5.30B | 6.1× | |
| 2023-06-30 | $5.30B | 5.2× | |
| 2022-06-30 | $8.60B | 9.4× | |
| 2021-06-30 | $7.67B | 5.7× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| Long-term debt / equity | 11.47x | 97th | |
| SBC / revenue | 1.2% | 6th | |
| Effective tax rate | 56.0% | 94th | |
| Net margin | 3.0% | 79th | |
| FCF margin | 8.7% | 78th | |
| Current ratio | 1.82x | 26th | |
| Gross margin | 53.3% | 30th | |
| Revenue YoY growth | -2.9% | 39th | |
| CapEx / revenue | 2.6% | 56th |
Organon & Co. (OGN) reported revenue of $6.10B and net income of $213.00M for the fiscal year ended 2026-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Organon & Co.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-09-30 |
|---|---|
| Revenue | $6.10B |
| Cost of revenue | $2.86B |
| Gross profit | $3.24B |
| Operating income | Unavailable |
| Net income | $213.00M |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $503.00M |
| Income tax expense | $290.00M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $1.71B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-09-30 |
|---|---|
| Cash & equivalents | $1.46B |
| Total assets | $13.40B |
| Current assets | $5.37B |
| Total liabilities | $12.21B |
| Current liabilities | $2.65B |
| Total equity incl. NCI | $1.19B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $1.36B |
| Accounts receivable | $1.48B |
| Goodwill | $4.15B |
| Long-term debt | $8.48B |
| Accounts payable | $982.00M |
Cash flow
| Metric | 2026-09-30 |
|---|---|
| Operating cash flow | $843.00M |
| Capital expenditures | $168.00M |
| Investing cash flow | $201.00M |
| Financing cash flow | -$242.00M |
| Net change in cash | $783.00M |
| Stock-based compensation | $72.00M |
| Common dividends paid | $20.00M |
| Common share repurchases | Unavailable |
| Depreciation & amortization | Unavailable |
Derived
| Metric | 2026-09-30 |
|---|---|
| Free cash flow | $675.00M |
| Gross margin | 53.1% |
| Operating margin | Unavailable |
| FCF margin | 11.1% |
| SBC / revenue | 1.2% |
| Current ratio | 2.02x |
| Revenue YoY growth | -3.2% |
| Net margin | 3.5% |
| R&D / revenue | Unavailable |
| CapEx / revenue | 2.8% |
| Long-term debt / equity | 7.11x |
| Effective tax rate | 57.7% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open OGN in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.